Overview

Type III Dysbetalipoproteinemia

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Lipid Regulating Agents
Pravastatin
Rosuvastatin Calcium